Bioregulators & Organ Support
Cortagen
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Neural Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 20 mg
Dosing window: Morning
Receptor / target: Cerebral Cortex
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily | Take upon waking. |
| Weeks 3-4 | 2mg 1x Daily | Take upon waking. Repeat every 6 months. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: Extended Protocol (Goal: general cortical aging normalization with minimized peak concentration variability; preferred for sensitive subjects)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg daily upon waking | Smoother absorption profile. Lower daily peak than 10-day 10mg course with broader time-exposure profile. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Cognitive Performance Optimization Protocol (Goal: peak cognitive output enhancement for high-demand intellectual work periods; time cycle to coincide with critical project phases)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 1mg 1x Daily upon waking | Ramp phase. Cortical activation enhancement begins accumulating. |
| Days 6-14 | 2mg 1x Daily upon waking | Full dose. Time the peak cycle to coincide with highest-demand cognitive work. |
| Days 15-28 | 2mg 1x Daily upon waking | Extended maintenance phase for sustained cognitive enhancement through the work period. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3: Post-Stroke or TBI Cortical Recovery Protocol (Goal: cortical neuroplasticity and synaptic density restoration following ischemic stroke or traumatic brain injury; minimum 6 weeks post-event, neurologist clearance required)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500 mcg 1x Daily upon waking | Conservative entry. Requires neurologist clearance. Minimum 6 weeks post-acute neurological event. |
| Weeks 3-4 | 1mg 1x Daily upon waking | |
| Weeks 5-8 | 2mg 1x Daily upon waking | Full therapeutic dose. Run concurrently with Cerebrolysin for maximal neurotrophic support. |
| Weeks 9-12 | 2mg 1x Daily upon waking | Extended cycle appropriate for stroke/TBI recovery context. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4: Early Neurodegeneration Intervention Protocol (Goal: early-stage MCI or vascular dementia: cortical bioregulator support combined with Pinealon + Cerebrolysin triple CNS stack; neurologist supervision)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-3 | 500 mcg 1x Daily upon waking | Entry dose. Run Pinealon concurrently at its standard dose. Stagger Cerebrolysin to begin on Day 5. |
| Days 4-10 | 1mg 1x Daily upon waking | |
| Days 11-20 | 2mg 1x Daily upon waking | Full combined CNS stack at target doses. Assess cognitive function markers at day 20 baseline and 60-day follow-up. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 5: Seasonal Cognitive Maintenance Protocol (Goal: twice-yearly cortical bioregulator support for healthy aging subjects; biannual schedule)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 (Q1) | 1mg 1x Daily upon waking | Cycle 1 ramp. |
| Weeks 3-4 (Q1) | 2mg 1x Daily upon waking | Cycle 1 full dose. |
| Weeks 1-2 (Q3) | 1mg 1x Daily upon waking | Cycle 2 ramp. ~6-month separation produces consistent cortical bioregulator exposure across the year. |
| Weeks 3-4 (Q3) | 2mg 1x Daily upon waking | Cycle 2 full dose. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Cerebral Cortex); route Subcutaneous; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active seizure disorders not under pharmacological control: cortical bioregulator activity affecting neuronal excitability and synaptic signaling has not been evaluated in subjects with uncontrolled epilepsy; any compound affecting cortical neuronal gene programs in the context of pathological hyperexcitability warrants medical supervision. Limited / unverified
- Active CNS infection (meningitis, encephalitis): exogenous cortical bioregulator activity during active brain infection could interfere with the CNS immune response and neuroinflammatory defense mechanisms. Limited / unverified
- Concurrent use with CNS-active medications requiring stable plasma levels (narrow therapeutic index antiepileptics, MAOIs, lithium): while no direct pharmacokinetic interactions are documented, any compound affecting neuronal function in subjects on narrow-index CNS drugs warrants awareness. Limited / unverified
- Known hypersensitivity to Cortagen (Ala-Glu-Asp-Pro tetrapeptide) or formulation excipients. Limited / unverified
- Pregnancy: cortical neurodevelopmental processes during fetal brain formation are tightly regulated; exogenous cortical bioregulator activity has not been characterized during fetal CNS development. Limited / unverified
- Severe psychiatric disorders in acute phase (psychosis, severe mania): cortical gene program modulation in subjects with acute cortical dysregulation from psychiatric disease may produce unpredictable effects. Limited / unverified
- Active malignant brain tumors: bioregulator normalization of cortical cell gene programs in the context of CNS malignancy where tumor cells may express cortical tissue receptors has not been characterized. Limited / unverified
Side effects (limited evidence)
- Increased dream vividness: the cortical activation enhancement from Cortagen in the morning can produce increased REM activity in subsequent sleep; some subjects report more vivid and memorable dreams during Cortagen cycles. Limited / unverified
- Mild headache on cycle initiation: uncommonly reported in the first 1-3 days as cortical metabolic activity normalizes; typically self-limiting. Limited / unverified
- Increased energy and alertness: a commonly reported desired effect rather than an adverse event; the morning dosing timing is designed to leverage this cortical activation enhancement for daytime cognitive performance. Limited / unverified
- Mild mood elevation: the improvements in cortical BDNF-pathway-related neuroplasticity mechanisms can produce subjective mood brightening; typically mild and within the normal range. Limited / unverified
- Potential overstimulation in sensitive subjects: subjects who are already highly cognitively activated (high-stress periods, concurrent stimulant use) may find the cortical activation effects of Cortagen amplifying to an uncomfortable degree; managed by dose reduction or timing adjustment. Limited / unverified
- Injection site mild reaction: standard subcutaneous peptide response. Limited / unverified
- No serious neurological adverse events documented in the Khavinson research literature: Cortagen's published safety profile across aging and neurological disease research populations is clean at standard protocol doses. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.